-
Epigenetic modifiication & Histone methylation(Post)
Agata Miezaniec PhD Candidate, University of Nottingham, UK Epigenetics and the link to DNA Methylation The term ‘Epigenet
TLR4: Unraveling the Role of Inflammation in Cancer Progression(Post)Introduction to TLR4 and Cancer Toll-like receptor 4 (TLR4) is a key component of the innate immune system, primarily responsible for detecting infections and initiating inflammatory resp
Treg Suppression and the IL-2 Axis: Pathway, Function and Assays(Post)Regulatory T cells cannot make the cytokine they depend on. FOXP3 represses the Il2 locus, so every Treg lives on IL-2 secreted by the conventional T cells it exists to restrain. That asymmetry expla
Guide to Western Blot Sample Preparation(Post)Protein Analysis · ProtocolsWestern Blot Sample Preparation: A Practical GuideMost failed Western blots fail before the gel is loaded. Lysis buffer choice, inhibitor selection, accurate protein quanti
Secondary Antibodies(Page)Secondary Antibodies | HRP, FITC, Cy3 & AP Conjugates | Assay Genie
Agonist Antibodies: Why CD40, OX40 & 4-1BB Need FcγR Crosslinking(Page) The Exciting Field of Stem Cell Research(Post)What are Stem Cells? Stem cells are primitive, undifferentiated, and unspecialised cells that are found in multicellular organisms
Elotuzumab: Revolutionizing Multiple Myeloma Treatment and Research Applications(Post)Quick Facts About ElotuzumabWhat is Elotuzumab?Elotuzumab is a monoclonal antibody designed to enhance the immune system's ability to detect and destroy multiple myeloma cells. It target
Ferroptosis: A New Frontier in Cancer Therapy(Post)For decades, the primary strategy in cancer treatment has been to trigger apoptosis, a form of programmed cell death, in malignant cells. However, many cancers develop resistance to apoptosis-inducin
Fc Receptors & Antibody Effector Function(Page) AKT Signalling – Mini Review(Post)Protein kinase B or AKT (PKB) is a serine/threonine kinase. In mammals it is comprised of 3 highly homologous isoforms PKBα (Akt1), PKBβ (Akt2), and PKBγ (Akt3) (Manning and Cantley 2007). AKT
인터루킨 8 시그널링(Page) CD47: Overcoming Tumor Evasion Through Macrophage Activation(Post)One of the greatest challenges in cancer therapy is how tumors evade immune detection. Among the mechanisms cancer cells exploit, the CD47 pathway has emerged as a major player in helping
Macrophage, M1 & M2, Polarization and Function(Post)What is a Macrophage? Macrophages are indeed a type of phagocyte, responsible for engulfing and destroying foreign particles and cellular debris. They are larger cells with more cytoplasm an
Turning Tumors Against Themselves: In Vivo Reprogramming of Cancer Cells into Dendritic Sentinels(Post)Imagine a future where cancer cells, once masters of disguise, are forced to reveal themselves and even train the body's immune system to fight back. This isn't science fiction; it's the groundbreaki
Your Agonist Antibody Is Not an Agonist(Post)An agonist antibody does not activate its receptor. It gets held still by something else, and the receptors underneath cluster because they are crowded. That sentence sounds like a technicality and i
Uliledlimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking CD
Unconventional T Cells: Already Armed, and No MHC Required(Post)Most immunology is written as though a T cell must first be told what to look for. Three lineages did not read that memo. γδ T cells, invariant NKT cells and MAIT cells leave the thymus with their ef
How Cancer Cells Hijack Immune Defenses Through Mitochondrial Transfer(Post)Imagine a battlefield where the enemy doesn't just hide from soldiers—it actively sabotages their weapons. In the tumor microenvironment, cancer cells have evolved a devious strategy: they transfer th
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies(Post)1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive compon